ADMA Biologics, Inc.

Quick facts

Marketed products

• Asceniv™ · Immunology
  Asceniv is an intravenous immunoglobulin (IVIG) replacement therapy that provides polyclonal antibodies to boost immune function in patients with primary immunodeficiency.
• Bivigam · Other

Phase 3 pipeline

• RI-002 · Immunology
  RI-002 is an intravenous immunoglobulin (IVIG) product that provides passive immunity by delivering polyclonal human antibodies to boost immune function.

Phase 2 pipeline

• RI-001

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• ADMA Biologics, Inc. portfolio CI brief
• ADMA Biologics, Inc. pipeline updates RSS